Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Inozyme Pharma, Inc.

Get SEC filing alerts via email and in your feed for Inozyme Pharma, Inc.

INZY

Inozyme Pharma, Inc.

About Inozyme Pharma, Inc.

Inozyme Pharma is a clinical-stage biopharmaceutical company developing therapies targeting rare diseases affecting bone mineralization and blood vessel function. Its lead product, INZ-701, is designed to increase PPi and adenosine levels to treat conditions like ENPP1 and ABCC6 deficiencies, calciphylaxis, and related disorders. The company focuses on innovative biologics, leveraging its expertise in the PPi-Adenosine pathway to address unmet medical needs in systemic calcification and vascular diseases.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Inozyme Pharma, Inc.

1
1
Inozyme Pharma, Inc. Inozyme Pharma Reports $28M Net Loss in Q1 2025, Announces Workforce Reduction

Via official filing (AI summary) | about 1 year ago | 0 comments

2
1
Inozyme Pharma, Inc. Inozyme Pharma Reports Financial Results, Advances Clinical Trials for Lead Product Candidate INZ-701

Via official filing (AI summary) | over 1 year ago | 0 comments